Register today for our live fireside chat with Frost & Sullivan on April 15th at 8am PST |  11am EST | 4pm GMT to discover a more streamlined approach for developing next-gen bioconjugates.

As the bioconjugate landscape continues to accelerate, drug developers are re-evaluating how to de-risk development while compressing timelines from discovery to GMP supply. For those working on ADCs, AOCs, and other emerging modalities, traditional fragmented development models introduce compounding risks: technical transfer delays, process inconsistencies, and costly late-stage failures that set programs back — or kill them entirely.

In this fireside chat, Frost & Sullivan’s Unmesh Lal sits down with Abzena’s scientific leadership to explore how a fully integrated CDMO+CRO model is challenging conventional thinking and laying out a new blueprint — one where integration, not fragmentation, is the key to reducing risk without sacrificing speed.

Anchored in Frost & Sullivan’s view of a rapidly growing Biologics CDMO market, where mammalian drug substance (DS) remains the workhorse and ADCs drive value chain expansion, the discussion will translate market signals into practical playbooks for emerging biotechs and pharma alike.

Abzena’s scientific leaders will draw on two decades of bioconjugation expertise and a dual US–UK operating footprint to walk through how end-to-end integration spanning discovery, cell line development, advanced analytics, bioconjugation, linker-payload chemistry, upstream & downstream process development, and GMP manufacturing — eliminates the handoff friction that derails timelines and drives up cost. With large-scale antibody production capabilities, high-potency handling, and a platform built for “getting-it-right-from-the-start” execution, Abzena’s integrated model is purposefully designed to confidently move bioconjugate programs from the bench to clinic and toward commercialization faster.

You’ll leave with actionable insights on:

• How an integrated development model reduces technical & operational risk across next-gen modalities
• Early development strategies that front-load risk identification & mitigation before it becomes costly
• Partner and technology selection criteria — what to look for and what to avoid
• Navigating the evolving regulatory landscape for novel bioconjugate modalities
• Fast-track execution strategies that compress the discovery-to-GMP timeline without compromising quality

Click Here to Register

Panelists: